The emergence of drug resistance complicating anti-human immunodeficiency virus type 1 (HIV-1) therapy remains a significant limitation in the clinical utility of inhibitors directed against specific HIV enzymatic targets. Viral resistance is a direct consequence of genetic diversity. The inherent
No takes yet. Share an insight, caveat, or question.
Boden et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: